BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
BioCryst presented two real-world studies at the ACAAI 2026 Annual Scientific Meeting reporting reduced healthcare resource use among HAE patients who initiated ORLADEYO or switched to it from another prophylactic therapy. The reported reductions included angioedema-related medical visits.
Why it matters — The findings provide real-world evidence about healthcare resource utilization associated with ORLADEYO, BioCryst’s HAE prophylactic therapy.